Studies on paediatric pulmonology from the UK and Sweden have demonstrated that both young and adult patients with respiratory disease can achieve good quality spirometry at home, without clinical supervision, when using the NuvoAir Home platform.
The platform includes in-app coaching which provides feedback on techniques to support quality measurements.
Other key findings show that patient adherence to self-monitoring schedules is high and that the technology is well accepted by patients and parents.
HIMSS20 Digital
WHY IT MATTERS
The platform allows patients to self-monitor their respiratory health and share clinically relevant data with their care teams, who can view these data remotely via a healthcare portal.
NuvoAir analytics help to assess changes in the respiratory status of each patient, enabling clinical teams to optimise the follow-up and care of their patients.
The first study, from the Royal Brompton Hospital, showed that the quality of 783 unsupervised home spirometry sessions performed by 37 adult patients with NuvoAir, over nearly one year, was equivalent to the quality of the first supervised spirometry session at the hospital with NuvoAir. In addition, adherence to a spirometry regime of twice a month was high.
Results from the second study, conducted at the Royal London Hospital, showed that 74% of 30 adolescent CF and bronchiectasis patients were able to perform reproducible spirometry over a six week period according to the European Respiratory Society (ERS)/American Thoracic Society (ATS) technical standards. These tests were performed at home and independently, without clinician supervision.
Furthermore, a Swedish study from the Sahlgrenska University Hospital, which piloted virtual clinics supported by NuvoAir, showed that children aged 6-17 years old with CF could perform correct spirometry tests at home according to ATS/ERS criteria.
THE LARGER CONTEXT
In August, NuvoAir received Class Im medical device status and in April 2018, it unveiled its newest version of its home-use spirometer, dubbed the Air Next, which also received a CE Mark as a Class lla medical device.
ON THE RECORD
NuvoAir’s CEO, Lorenzo Consoli said: “We are delighted to see a growing body of evidence demonstrating the value of our platform. The ability to empower both children and adults to perform high quality measurements from home is essential for clinicians to make the right clinical decisions. High-quality data coupled with strong adherence and patient satisfaction represent the foundation of NuvoAir’s product strategy.”